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The incidence and temporal trends of psoriasis in Den-
mark between 2003 and 2012 were examined. There 
was a female predominance ranging between 50.0% 
(2007) and 55.4% (2009), and the mean age at time 
of diagnosis was 47.7–58.7 years. A total of 126,055 
patients with psoriasis (prevalence 2.2%) were iden-
tified. Incidence rates of psoriasis (per 100,000 person 
years) ranged from 107.5 in 2005 to a peak incidence 
of 199.5 in 2010. Incidence rates were higher for wo-
men, and patients aged 60–69 years, respectively. Use 
of systemic non-biologic agents, i.e. methotrexate, 
cyclosporine, retinoids, or psoralen plus ultraviolet 
A (PUVA) increased over the study course, and were 
used in 15.0% of all patients. Biologic agents (efalizu-
mab, etanercept, infliximab, adalimumab, or ustekinu-
mab) were utilized in 2.7% of patients. On a national 
level, incidence of psoriasis fluctuated during the 10-
year study course. The relationship between psoriasis 
incidence and age appeared to be relatively linear, and 
disease prevalence was comparable to that in other 
European countries.
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Psoriasis is a prevalent chronic inflammatory disease characterized by localized or widespread, thick, 
silvery-white, scaly, pruritic plaques. The exact aetiology 
of psoriasis is not fully understood, but both genetic 
and environmental factors are involved in the onset and 
progression of the disease (1). Approximately 70–80% 
of all patients with psoriasis are considered to have mild 
disease that can be managed with topical treatment alone 
(2, 3). Studies have shown that psoriasis negatively af-
fects patients’ quality of life, and that depression occurs 
more often than in controls (2, 4, 5). Along this line, 
studies have also shown that psoriasis is a systemic di-
sease, which also affects the joints, vasculature and other 
tissues. Indeed, approximately one-third of patients with 
psoriasis develop psoriatic arthritis, and patients with 
severe psoriasis have a shortened life expectancy as well 
as several major comorbidities (6, 7). 
While most recent epidemiological studies have 
examined comorbidities in psoriasis, potential changes 
in disease prevalence and incidence are less common. 
Based on past studies, psoriasis is estimated to affect ap-
proximately 2–4% of the population in western countries 
(8); however, the prevalence varies with age, sex, geo-
graphy and ethnicity. For example, while some studies 
have suggested that the onset of psoriasis is bimodal, 
with peaks at ages between 15 and 20 years and, later, 
at between 55 and 60 years (2), others have described 
that the prevalence increases are roughly linear over the 
life-course (3). Since few studies on psoriasis prevalence 
in Denmark have been published (9–11), we examined 
the time trend in incidence, as well as the prevalence of 
psoriasis in a Danish nationwide cohort.
MATERIALS AND METHODS
Data sources and study population
Study approval was obtained from the Danish Data Protection 
Agency (ref. 2007-58-0015, int. ref. GEH-2014-018, I-Suite 
02736). Approval from an ethics committee is not required for re-
gistry studies in Denmark. The study was conducted in accordance 
with the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) recommendations (12). 
Using the unique personal identification number assigned to 
all Danish citizens, individual-level information from nationwide 
administrative registers was linked. The Civil Registration Sys-
tem (13) contains information on sex, date of birth, and updated 
information on vital status and emigration, thus minimizing loss 
to follow-up. All inpatient and outpatient (ambulatory) hospital 
consultations are recorded in the Danish National Patient Regis-
ter (DNPR) (14) including one primary and up to 19 secondary 
diagnoses coded by discharging physicians according to the In-
ternational Classification of Diseases, 8th revision (ICD-8) (prior 
to 1994), and according to the 10th revision (ICD-10) thereafter. 
The primary diagnosis is the main reason for the hospital consul-
tation or hospitalization, and secondary diagnoses are additional 
conditions, including complications. The DNPR was established in 
1977, and outpatient data has been available from 1995 onwards. 
Since 1994, detailed and accurate information on all pharmacy-
dispensed medications has been registered in the Danish Registry 
of Medicinal Products Statistics according to the Anatomical 
Therapeutic Chemical (ATC) classification (15). Hospital ad-
ministered pharmacotherapy is coded in the DNPR as treatment 
procedure (SKS) codes. We defined patients with incident psoriasis 
as those recorded with a corresponding first-time ICD-10 code 
(L40) or an ATC code for pharmacotherapy for use exclusively in 
psoriasis (D05AX), and thus excluded all patients with a history 
of psoriasis based on the above criteria before 1 January 2003 in 
analyses of incident psoriasis. When examining the prevalence of 
psoriasis, these patients were not excluded. The study period was 
divided into 1-year groups from 2003 to 2012. We identified use of 
systemic therapy, i.e. methotrexate, cyclosporine, PUVA, retinoids, 
efalizumab, etanercept, infliximab, adalimumab, and ustekinumab.
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Statistical analysis
The number of incident psoriasis cases within each of the prede-
fined 1-year periods was estimated and the frequency of psoriasis 
cases within sex and age subgroups (0–19, 20–29, 30–39, 40–49, 
50–59, 60–69, 70+ years) calculated. The incidence rate within 
each 1-year period was computed as the number of newly diag-
nosed psoriasis cases divided by the risk time of the underlying 
population. The population size in each of the 1-year periods was 
estimated as the number of Danes alive in the mid-year of each 
period, as recorded in the Civil Registration System, and the risk 
time as 1 year times the estimated number of Danes in each period. 
The prevalence of psoriasis was estimated among all Danes alive 
and resident in the source population on 31 December 2012. Due 
to data security requirements, data on 1 or 2 subjects are shown 
as “less than 3”, and the derived percentages are not shown. SAS 
statistical software version 9.4 (SAS Institute Inc. Cary, NC, USA) 
was used for statistical analysis. 
RESULTS
During the study period, the total Danish population com-
prised approximately 5.7 million individuals with nearly 
equal sex distribution. Among patients with psoriasis 
there was a slight female predominance, ranging from 
50.0% (2007) to 55.4% (2009/2010), and the mean age at 
time of diagnosis was between 47.7 and 48.7 years (Table 
I). The incidence of psoriasis (presented as incidence ra-
tes per 100,000 person-years) ranged from 107.5 in 2005 
to a peak incidence of 199.5 in 2010 (Fig. 1 and Table II). 
Estimates with 25% error margins are shown in Fig. 2. 
The highest percentage of patients with incident psoriasis 
was initially observed among individuals aged between 
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Fig. 1. Incidence rates of psoriasis. Total and sex-specific incidence 
rates per 100,000 person-years of psoriasis over the study period 2003 
to 2012. Blue: overall; Red: women; Green: men.
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Fig. 2. Incidence rates of psoriasis, with 95% confidence intervals.
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50 and 59 years, but during the study course there was 
a shift towards a higher incidence in individuals aged 
between 60 and 69 years. Incident psoriasis was least 
frequent among younger individuals aged 0–19 years 
(Table I and Fig. 3). Similarly, age-specific incidence 
rates were highest among subjects aged 60–69 years 
and lowest among individuals aged 0–19 years (Fig. 4). 
Use of systemic non-biologic agents increased over 
the 10-year study course. The first recorded use of bio-
logic agents for patients classified with psoriasis within 
the same year, occurred in 2004, after which their use 
steadily increased (Table I).
As shown in Table III, a total of 126,055 patients with 
psoriasis were identified (prevalence 2.2%), and patients 
were predominantly female (54%) with a mean age of 45 
years. The highest prevalence was among patients aged 
60–69 years, followed by those aged 50–59 years (Table 
III and Fig. 5). Fifteen percent of patients had received 
treatment with systemic non-biologic immunosuppres-
sants, whereas biologics were used in 2.7% of patients 
(Table III). 
DISCUSSION
In this nationwide study of the Danish population, an 
overall psoriasis prevalence of 2.2% was identified. We 
described the temporal trends in the incidence of psoriasis 
between 2003 and 2012, and found the highest incidence 
among older individuals and females. Fifteen percent of 
patients received treatment with systemic non-biologic 
therapy, and one-fifth of patients were treated with bio-
logics at some point.
While a number of studies from different countries 
have examined the prevalence of psoriasis (8), the pre-
valence in Denmark remains poorly characterized. One 
previous survey-based study from 1981 examined the 
prevalence of psoriasis in Denmark among individuals 
aged 16–99 years (9) in which the estimated point preva-
lence was 3.2% and 2.5% for men and women, respecti-
vely. Moreover, it was estimated that a total of 113,000 
Danish residents had psoriasis, whereas 2 survey-based 
studies indicated a prevalence of 3–4% (10, 11). On the 
other hand, a 1964 study from the Faroe Islands reported 
a psoriasis prevalence of 2.8% (16). Data from other 
Scandinavian countries have shown similar results, with 
an overall prevalence of 2.0% (women 2.3%; men 1.5%) 
in Sweden (8), and a somewhat lower prevalence among 
children (girls 2.3%; boys 1.5%) (17). While older Nor-
wegian studies have reported a prevalence of 1.4% (18, 
19), newer data suggest that the prevalence in Norway 
may be as high as 8.5% (20). However, a fundamental 
limitation of the abovementioned studies is the cross-
sectional design, since temporal changes in incidence 
and prevalence of psoriasis may occur. 
We found a higher incidence of psoriasis among wo-
men. Similar findings have been reported in some, but 
not all, studies (8). Although speculative, it is plausible 
that men may not seek medical treatment for their pso-
riasis and thereby go undiagnosed to a greater extent than 
women. Because of its nationwide and population-based 
design within a setting with equal access to healthcare 
for the entire population, the risk of referral and selec-
tion bias is arguably very low, and our study is likely to 
provide highly generalizable results. Nonetheless, certain 
limitations need to be addressed. Despite unfettered ac-
cess to healthcare in Denmark, including general practi-
tioners and hospitals, it is likely that some patients may 
not seek medical treatment for their psoriasis, resulting 
Table II. Incidence rates per 100,000 person-years of psoriasis in Denmark, 2003 to 2012
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Overall 140.13 122.22 104.01 105.47 111.45 128.62 174.81 180.99 171.27 151.21
Women 146.80 130.70 107.47 110.43 110.77 128.83 192.60 199.48 187.92 165.90
Men 133.35 113.62 100.50 100.44 112.15 128.40 156.83 162.31 154.46 136.39
Data are shown as incidence rates per 100,000 person-years.
Fig. 3. Distribution of incident psoriasis, stratified by age.
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
0-19 9.2 10.0 9.2 9.5 8.7 8.8 9.5 10.0 10.1 10.0 
20-29 10.5 10.3 9.9 9.8 10.7 10.8 10.6 10.9 11.4 12.3 
30-39 14.8 15.1 14.4 15.4 15.0 13.8 14.1 14.0 14.1 13.2 
40-49 15.8 15.0 16.8 15.7 16.0 16.7 15.3 15.9 15.2 15.0 
50-59 21.8 21.1 20.9 20.7 19.9 19.2 18.5 17.7 18.0 17.0 
60-69 14.9 16.1 16.3 15.8 17.7 18.7 18.5 18.0 17.8 18.0 
70 13.1 12.4 12.6 13.1 12.0 11.9 13.5 13.5 13.5 14.6 
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in conservative estimates of incidence and prevalence, 
and a bias towards a higher incidence in older age due 
to diagnostic delay. While some studies have suggested 
a bimodal peak in psoriasis incidence, the somewhat 
linear increase observed in our study is in line suppor-
ted by Boehncke & Schon, stating that the increase is 
“roughly linear over the life course” (3). Also, patients 
in primary or secondary care who were treated with 
topical corticosteroids alone or ultraviolet B (UVB) tre-
atment were not included, as these would not have been 
captured in the DNPR. However, in Denmark, topical 
vitamin D analogues are the preferred first-line therapy 
for psoriasis, and used in 94% of patients with psoriasis 
(21). Nevertheless, assuming a 25% error margin in the 
prevalence of psoriasis, the most conservative and liberal 
estimates would yield 94,541 (prevalence 1.7%) and 
157,569 (prevalence 2.8%), respectively. Nevertheless, 
we identified psoriasis based on either a diagnosis or use 
of highly psoriasis-specific pharmacotherapy. However, 
since all patients were not necessarily diagnosed by 
dermatologists, we cannot refute that some misclassifi-
cation may have occurred, since studies have suggested 
that psoriasis can be difficult to diagnose, especially in 
children (22). Misclassification of patients with psoriasis 
as having other skin disease, or if patients did not seek 
medical attention, would lead to an underestimation of 
the true incidence and prevalence. On the other hand, 
if patients with other skin disease were misclassified 
as having psoriasis, this would lead to an overestima-
tion of incidence and prevalence. However, we believe 
that such misclassification would be non-differential 
between the different time points (2003 to 2012) and is 
unlikely to explain the observed time trends. The gene-
ral population distribution has been stable in Denmark 
during the current study period. Nevertheless, in Fig 2, 
a more conservative approach has been applied to show 
the estimated time trends in psoriasis incidence in Den-
mark. Indeed, assessment of incidence of psoriasis is a 
fundamental issue in all large-scale settings because of 
the difficulty in accurately identifying and documenting 
such cases. Indeed, given the considerations listed above, 
the present findings should be interpreted accordingly 
and with caution. 
In conclusion, the incidence of psoriasis fluctuated 
during the 10-year study period, albeit that we did not 
observe a marked increase. The disease prevalence was 
comparable to recent studies from other Scandinavian 
countries.
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Table III. Characteristics and prevalence of patients with psoriasis 
on 31 December 2012
n %
Population 5,677,138
Women 2,854,985 50.29
Men 2,822,153 49.71
Psoriasis 
Mean age, years 44.6
Any 126,055 2.22
Women 67,532 53.57
Men 58,523 46.43
Age groups
0–19 years 4,953 3.93
20–29 years 9,411 7.47
30–39 years 14,897 11.82
40–49 years 21,681 17.20
50–59 years 24,195 19.19
60–69 years 27,322 21.67
≥70 years 23,596 18.72
Systemic treatments*
Any 19,276 15.29
Non-biologic 18,933 15.02
Biologic 3,379 2.68
*Systemic treatments=methotrexate, cyclosporine, retinoids, psoralen plus 
ultraviolet A (PUVA), efalizumab, etanercept, infliximab, adalimumab, ustekinumab.
Fig. 4. Age-specific incidence rates of psoriasis per 100,000 person-
years over the study period 2003 to 2012.
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Fig. 5. Distribution of prevalent psoriasis (% with psoriasis of all 
Danish residents) on 31 December 2012, stratified by age.
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